Inactivation of NF-κB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5780-5788

  Yamamoto, Mizuki ^a   Horie, Ryouichi ^b   Takeiri, Masatoshi ^a   Kozawa, Ikuko ^a   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; CYSTEINE; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR REL; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; PRIMER DNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; COVALENT BOND; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; STOICHIOMETRY; SYNTHESIS; WESTERN BLOTTING; ANIMAL; BINDING SITE; DRUG ANTAGONISM; GEL MOBILITY SHIFT ASSAY; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BENZAMIDES; BINDING SITES; CELL LINE, TUMOR; CYCLOHEXANONES; CYSTEINE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; SURFACE PLASMON RESONANCE;

EID: 52449131840     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8006245     Document Type: Article

References (38)

1. Schmitz, M. L.; Mattioli, I.; Buss, H.; Kracht, M. NF-κB: A multifaceted transcription factor regulated at several levels. ChemBioChem 2004, 5, 1348-58.
2. Plaksin, D.; Baeuerle, P. A.; Eisenbach, L. KBF1 (p50 NF-κB homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J. Exp. Med. 1993, 177, 1651-62.
3. Baeuerle, P. A.; Baltimore, D. NF-κB: Ten years after. Cell 1996, 87, 13-20.
4. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. Cell 2002, 109, 81-96.
5. Chen, Z.; Hagler, J.; Palombella, V. J.; Melandri, F.; Scherer, D.; Ballard, D.; Maniatis, T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 1995, 9, 1586-97.
6. Fagerlund, R.; Kinnunen, L.; Köhler, M.; Julkunen, I.; Melén, K. NF-{κ}B is transported into the nucleus by importin {α}3 and importin {α}4. J. Biol. Chem. 2005, 280, 15942-51.
7. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F. R.; Krähn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S. C.; Karin, M. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001, 293, 1495-9.
8. Matsumoto, N.; Ariga, A.; To-e, S.; Nakamura, H.; Agata, N.; Hirano, S.; Inoue, J.; Umezawa, K. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 2000, 10, 865-9.
9. Suzuki, Y.; Sugiyama, C.; Ohno, O.; Umezawa, K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 2004, 60, 7061-6.
10. Ariga, A.; Namekawa, J.; Matsumoto, N.; Inoue, J.; Umezawa, K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 2002, 277, 24625-30.
11. Wakamatsu, K.; Nanki, T.; Miyasaka, N.; Umezawa, K.; Kubota, T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res. Ther. 2005, 7, R1348-59.
12. Miyajima, A.; Kosaka, T.; Seta, K.; Asano, T.; Umezawa, K.; Hayakawa, M. Novel nuclear factor κB activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J. Urol. 2003, 169, 1559-63.
13. Kuroda, K.; Horiguchi, Y.; Nakashima, J.; Kikuchi, E.; Kanao, K.; Miyajima, A.; Ohigashi, T.; Umezawa, K.; Murai, M. Prevention of cancer cachexia by a novel nuclear factor {κ}B inhibitor in prostate cancer. Clin. Cancer Res. 2005, 11, 5590-4.
14. Kubota, T.; Hoshino, M.; Aoki, K.; Ohya, K.; Komano, Y.; Nanki, T.; Miyasaka, N.; Umezawa, K. NF-κB inhibitor dehydroxymethyl-epoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res. Ther. 2007, 9, R97.
15. Kikuchi, E.; Horiguchi, Y.; Nakashima, J.; Kuroda, K.; Oya, M.; Ohigashi, T.; Takahashi, N.; Shima, Y.; Umezawa, K.; Murai, M. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 2003, 63, 107-10.
16. Starenki, D. V.; Namba, H.; Saenko, V. A.; Ohtsuru, A.; Maeda, S.; Umezawa, K.; Yamashita, S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004, 10, 6821-9.
17. Matsumoto, G.; Namekawa, J.; Muta, M.; Nakamura, T.; Bando, H.; Tohyama, K.; Toi, M.; Umezawa, K. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 2005, 11, 1287-93.
18. Matsumoto, G.; Muta, M.; Umezawa, K.; Suzuki, T.; Misumi, K.; Tsuruta, K.; Okamoto, A.; Toi, M. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor. Int. J. Oncol. 2005, 27, 1247-55.
19. Tatetsu, H.; Okuno, Y.; Nakamura, M.; Matsuno, F.; Sonoki, T.; Taniguchi, I.; Uneda, S.; Umezawa, K.; Mitsuya, H.; Hata, H. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner. Mol. Cancer Ther. 2005, 4, 1114-20.
20. Watanabe, M.; Ohsugi, T.; Shoda, M.; Ishida, T.; Aizawa, S.; Maruyama-Nagai, M.; Utsunomiya, A.; Koga, S.; Yamada, Y.; Kamihira, S.; Okayama, A.; Kikuchi, H.; Uozumi, K.; Yamaguchi, K.; Higashihara, M.; Umezawa, K.; Watanabe, T.; Horie, R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005, 106, 2462-71.
21. Umezawa, K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 2006, 97, 990-5.
22. García-Piñeres, A. J.; Lindenmeyer, M. T.; Merfort, I. Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. 2004, 75, 841-56.
23. Ryseck, R. P.; Weih, F.; Carrasco, D.; Bravo, R. RelB, a member of the Rel/NF-κB family of transcription factors. Braz. J. Med. Biol. Res. 1996, 29, 895-903.
24. Park, S. W.; Huq, M. D.; Hu, X.; Wei, L. N. Tyrosine nitration on p65: A novel mechanism to rapidly inactivate nuclear factor-κB. Mol. Cell. Proteomics 2005, 4, 300-9.
25. Qanungo, S.; Starke, D. W.; Pai, H. V.; Mieyal, J. J.; Nieminen, A. L. Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFκB. J. Biol. Chem. 2007, 282, 18427-36.
26. Straus, D. S.; Pascual, G.; Li, M.; Welch, J. S.; Ricote, M.; Hsiang, C. H.; Sengchanthalangsy, L. L.; Ghosh, G.; Glass, C. K. 15-Deoxy-δ-12,14- prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4844-9.
27. García-Piñeres, A. J.; Castro, V.; Mora, G.; Schmidt, T. J.; Strunck, E.; Pahl, H. L.; Merfort, I. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001, 276, 39713-20.
28. Han, Y.; Englert, J. A.: Delude, R. L.; Fink, M. P. Ethacrynic acid inhibits multiple steps in the NF-κB signaling pathway. Shock 2005, 23, 45-53.
29. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Gilmore, T. D. Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anticancer cell growth activity. Biochem. Pharmacol. 2006, 71, 634-45.
30. Chen, F. E.; Huang, D. B.; Chen, Y. Q.; Ghosh, G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature 1998, 391, 410-3.
31. Moorthy, A. K.; Huang, D. B.; Wang, V. Y.; Vu, D.; Ghosh, G. X-ray structure of a NF-κB p50/RelB/DNA complex reveals assembly of multiple dimers on tandem κB sites. J. Mol. Biol. 2007, 373, 723-34.
32. Cramer, P.; Larson, C. J.; Verdine, G. L.; Müller, C. W. Structure of the human NF-κB p52 homodimer-DNA complex at 2.1 A resolution. EMBO J. 1997, 16, 7078-90.
33. Watanabe, M.; Dewan, M. Z.; Taira, M.; Shoda, M.; Honda, M.; Sata, T.; Higashihara, M.; Kadin, M. E.; Watanabe, T.; Yamamoto, N.; Umezawa, K.; Horie, R. IκBa independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab. Invest. 2007, 87, 372-82.
34. Harhaj, E. W.; Sun, S. C. Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol. Cell. Biol. 1999, 19, 7088-95.
35. Lee, S. H.; Hannink, M. The N-terminal nuclear export sequence of IκBα is required for RanGTP-dependent binding to CRM1. J. Biol. Chem. 2001, 276, 23599-606.
36. Fukuda, M.; Asano, S.; Nakamura, T.; Adachi, M.; Yoshida, M.; Yanagida, M.; Nishida, E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390, 308-11.
37. Stemmer, W. P.; Morris, S. K. Enzymatic inverse PCR: A restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis. Biotechniques 1992, 13, 214-20.
38. Dignam, J. D.; Lebovitz, R. M.; Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11, 1475-89.